WRAP is a longitudinal study of a sample of over 1500 middle-aged adults predominantly between the ages of 40 and 65 years at baseline. In order to increase our power to detect decline (and associated predictors) in middle-age, the WRAP sample is enriched for a family history of Alzheimer's disease with over 70% of WRAP participants having a parent with either autopsy-confirmed or probable AD as defined by National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association research criteria [24 (link)]. Follow-up assessments are underway, with second wave assessments occurring approximately 4 years after baseline and all subsequent waves occurring at approximately 2 year intervals. As shown in Figure 1, WRAP has a very low attrition rate, with less than 5% of the baseline sample being unavailable for cognitive follow-up (e.g., deceased or dropped out). A large subset of the baseline sample had not yet returned for their third wave visit (n=831, 52.9%) and were therefore not included in analyses of our study hypotheses. To be included in testing the first hypothesis, participants must have completed three waves of testing, be free of dementia at or before the third wave of assessment, and be free of neurological conditions (including stroke, meningitis, epilepsy, multiple sclerosis, and Parkinson's Disease); 532 met these inclusion/exclusion criteria (see sample flow chart in Figure 1). To be included in analyses of hypotheses two and three, participants also had to meet aMCI criteria for one or more of the three psychometric aMCI approaches OR meet criteria for “Cognitively Healthy” across all three assessment waves.